Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes

Nagaraja M. Phani, Manik Vohra, Ananth Kakar, Prabha Adhikari, Shivashankara K. Nagri, Sydney C. D'Souza, Shashikiran Umakanth, Kapaettu Satyamoorthy, Padmalatha S. Rai

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin. Method: We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks. Results: Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level. Conclusion: The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.

Original languageEnglish
Pages (from-to)905-911
Number of pages7
JournalPharmacogenomics
Volume19
Issue number11
DOIs
Publication statusPublished - 01-01-2018

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes'. Together they form a unique fingerprint.

  • Cite this